• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 4Subject characteristics in randomized controlled clinical trials that examined migraine prevention in children

Drugs References for RCTs*Age
# RCTs / Mean
[Min to Max]
% Female
# RCTs / Mean
[Min to Max]
Baseline Frequency of Migraine/Month
# RCTs / Mean
[Min to Max]
Duration of Migraine, Years
# RCTs / Mean
[Min to Max]
Obesity, BMI
# RCTs / Mean
[Min to Max]
Family History of Migraine, %
# RCTs / Mean
[Min to Max]
Topiramate81-877 / 12.6
[10.5 to 14.2]
7 / 56.9
[31.0 to 71.4]
5 / 9.6
[4.1 to 17.3]
1 / 4.22 / 23.3
[21.7 to 24.9]
0
Divalproex69,73,961 / 14.21 / 55.01 / 17.201 / 23.20
Valproate69,73,961 / 9.81 / 33.91 / 7.9000
Propranolol77-802 / 9.5
[9.2 to 9.9]
4 / 40.6
[33.0 to 46.2]
3 / 10.3
[3.4 to 14.0]
1 / 4.003 / 66.8
[13.0 to 100.0]
Metoprolol751 / 11.31 / 39.51 / 5.41 / 4.700
Trazodone701 / 12.61 / 45.01 / 3.81 / 4.501 / 67.5
Nimodipine761 /12.21 / 51.41 / 3.2000
Clonidine71,721 / 11.02 / 41.4
[38.6 to 44.2]
1 / 3.5001 / 90.7
Magnesium741 / 12.01 68.61 / 10.51 / 3.500
Drug management891 / 12.71 / 54.61 / 4.01 / 2.800
Total17 / 11.8
[9.2 to 14.2]
20 / 49.9
[31.0 to 71.4]
16 / 8.4
[3.2 to 17.3]
6 / 3.6
[2.2 to 4.7]
3 / 23.3
[21.7 to 24.9]
5 / 75.0
[13.0 to 100.0]

BMI = body mass index; RCT = randomized controlled trial

*

Include multiple publications of RCTs.

Include multiple publications of RCTs.

From: Results

Cover of Migraine in Children: Preventive Pharmacologic Treatments
Migraine in Children: Preventive Pharmacologic Treatments [Internet].
Comparative Effectiveness Reviews, No. 108.
Shamliyan TA, Kane RL, Ramakrishnan R, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.